Lenalidomid Zentiva

Lenalidomide, the active ingredient in Lenalidomid Zentiva, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, pharmacies and clinics worldwide from its EU‑originated manufacturing sources, ensuring quality and regulatory compliance.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies.

Multiple myeloma: improves progression‑free survival and overall response rates. Myelodysplastic syndromes: reduces transfusion dependence and improves peripheral blood counts. Mantle cell lymphoma: induces tumor regression and extends overall survival.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels that may cause bleeding. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Rash: mild skin eruptions. - Constipation: difficulty passing stool.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe infections: opportunistic or life‑threatening infections.

Lenalidomide requires careful monitoring and specific safety measures. - Pregnancy: contraindicated; teratogenic risk requires strict pregnancy prevention programs. - Thromboembolism risk: assess patient history and consider prophylactic anticoagulation. - Hematologic monitoring: regular CBC to detect neutropenia or thrombocytopenia. - Infection vigilance: monitor for signs of infection and manage promptly. - Renal/hepatic impairment: adjust dosing based on organ function. - Store at ambient temperature: keep below 25 °C, in original container, protect from moisture and light.

Lenalidomide may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - Live vaccines: increased risk of vaccine‑derived infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce drug levels. - P‑gp inhibitors (e.g., amiodarone): modestly increase exposure. - Other myelosuppressive agents: additive bone‑marrow suppression. - NSAIDs: may exacerbate thrombocytopenia.